MCL-1 as a therapeutic target in SCFFBW7 deficient neoplasm


Ontology type: sgo:Patent     


Patent Info

DATE

2018-06-26T00:00

AUTHORS

WEI WENYI

ABSTRACT

Some embodiments are based on the discovery that proliferative diseases (e.g., neoplastic diseases, for example, tumors or cancers) having an FBW7 mutation or other FBW7 deficiency are sensitive to Mcl1 inhibiting agents, but resistant to pro-apoptotic drugs that do not inhibit Mcl1. Some embodiments provide methods of treating a proliferative disease based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of classifying a hyperproliferative cell or cell population, for example, a malignant cell or cell population based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of selecting a treatment regimen for treating a proliferative disease, for example, a malignant disorder, based on an assessment of FBW7 expression level or mutation status. More... »

Related SciGraph Publications

  • 2010-12-01. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer in BREAST CANCER RESEARCH
  • 2010-06-20. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer in NATURE CHEMICAL BIOLOGY
  • 2009-12-20. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival in NATURE
  • 2002-05-01. AP-1 as a regulator of cell life and death in NATURE CELL BIOLOGY
  • 2009-04-03. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics in NATURE REVIEWS CANCER
  • 2005-06-27. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 in ONCOGENE
  • 2009-03-08. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction in NATURE CELL BIOLOGY
  • 2008-02. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation in NATURE REVIEWS CANCER
  • 2011-03-02. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 in NATURE
  • 2003-12. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 in NATURE
  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2004-03. Inactivation of hCDC4 can cause chromosomal instability in NATURE
  • 2007-06-10. The ubiquitin-specific protease USP28 is required for MYC stability in NATURE CELL BIOLOGY
  • 2007-05-21. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers in NATURE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "WEI WENYI", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nature05886", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032175359", 
              "https://doi.org/10.1038/nature05886"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc2615", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023532012", 
              "https://doi.org/10.1038/nrc2615"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature08646", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041625366", 
              "https://doi.org/10.1038/nature08646"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncb1847", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049656389", 
              "https://doi.org/10.1038/ncb1847"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncb1601", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021277213", 
              "https://doi.org/10.1038/ncb1601"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature02313", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016242812", 
              "https://doi.org/10.1038/nature02313"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature09779", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050839842", 
              "https://doi.org/10.1038/nature09779"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/bcr2788", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040598960", 
              "https://doi.org/10.1186/bcr2788"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208841", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053064977", 
              "https://doi.org/10.1038/sj.onc.1208841"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nchembio.391", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020485821", 
              "https://doi.org/10.1038/nchembio.391"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc2290", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042298247", 
              "https://doi.org/10.1038/nrc2290"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncb0502-e131", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026096121", 
              "https://doi.org/10.1038/ncb0502-e131"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature02067", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004573428", 
              "https://doi.org/10.1038/nature02067"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2018-06-26T00:00", 
        "description": "

    Some embodiments are based on the discovery that proliferative diseases (e.g., neoplastic diseases, for example, tumors or cancers) having an FBW7 mutation or other FBW7 deficiency are sensitive to Mcl1 inhibiting agents, but resistant to pro-apoptotic drugs that do not inhibit Mcl1. Some embodiments provide methods of treating a proliferative disease based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of classifying a hyperproliferative cell or cell population, for example, a malignant cell or cell population based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of selecting a treatment regimen for treating a proliferative disease, for example, a malignant disorder, based on an assessment of FBW7 expression level or mutation status.

    ", "endDate": "2032-03-02", "id": "sg:patent.US-10006089-B2", "name": "MCL-1 as a therapeutic target in SCFFBW7 deficient neoplasm", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.239395.7", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-10006089-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-09-02T16:21", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/patent/patent_1.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-10006089-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-10006089-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-10006089-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-10006089-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    82 TRIPLES      15 PREDICATES      30 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-10006089-B2 schema:about anzsrc-for:06
    2 anzsrc-for:0601
    3 schema:author N86a9a301900147d8926f4fde2cc67448
    4 schema:citation sg:pub.10.1007/s00018-008-8637-6
    5 sg:pub.10.1038/nature02067
    6 sg:pub.10.1038/nature02313
    7 sg:pub.10.1038/nature05886
    8 sg:pub.10.1038/nature08646
    9 sg:pub.10.1038/nature09779
    10 sg:pub.10.1038/ncb0502-e131
    11 sg:pub.10.1038/ncb1601
    12 sg:pub.10.1038/ncb1847
    13 sg:pub.10.1038/nchembio.391
    14 sg:pub.10.1038/nrc2290
    15 sg:pub.10.1038/nrc2615
    16 sg:pub.10.1038/sj.onc.1208841
    17 sg:pub.10.1186/bcr2788
    18 schema:datePublished 2018-06-26T00:00
    19 schema:description <p id="p-0001" num="0000">Some embodiments are based on the discovery that proliferative diseases (e.g., neoplastic diseases, for example, tumors or cancers) having an FBW7 mutation or other FBW7 deficiency are sensitive to Mcl1 inhibiting agents, but resistant to pro-apoptotic drugs that do not inhibit Mcl1. Some embodiments provide methods of treating a proliferative disease based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of classifying a hyperproliferative cell or cell population, for example, a malignant cell or cell population based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of selecting a treatment regimen for treating a proliferative disease, for example, a malignant disorder, based on an assessment of FBW7 expression level or mutation status.</p>
    20 schema:endDate 2032-03-02
    21 schema:name MCL-1 as a therapeutic target in SCFFBW7 deficient neoplasm
    22 schema:recipient grid-institutes:grid.239395.7
    23 schema:sameAs https://app.dimensions.ai/details/patent/US-10006089-B2
    24 schema:sdDatePublished 2022-09-02T16:21
    25 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    26 schema:sdPublisher Nb2436289248740fbb69bc5def550b04f
    27 sgo:license sg:explorer/license/
    28 sgo:sdDataset patents
    29 rdf:type sgo:Patent
    30 N86a9a301900147d8926f4fde2cc67448 rdf:first N9247704e637a40339583e64bdedb2001
    31 rdf:rest rdf:nil
    32 N9247704e637a40339583e64bdedb2001 schema:name WEI WENYI
    33 rdf:type schema:Person
    34 Nb2436289248740fbb69bc5def550b04f schema:name Springer Nature - SN SciGraph project
    35 rdf:type schema:Organization
    36 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    37 rdf:type schema:DefinedTerm
    38 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    39 rdf:type schema:DefinedTerm
    40 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    41 https://doi.org/10.1007/s00018-008-8637-6
    42 rdf:type schema:CreativeWork
    43 sg:pub.10.1038/nature02067 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004573428
    44 https://doi.org/10.1038/nature02067
    45 rdf:type schema:CreativeWork
    46 sg:pub.10.1038/nature02313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016242812
    47 https://doi.org/10.1038/nature02313
    48 rdf:type schema:CreativeWork
    49 sg:pub.10.1038/nature05886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032175359
    50 https://doi.org/10.1038/nature05886
    51 rdf:type schema:CreativeWork
    52 sg:pub.10.1038/nature08646 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041625366
    53 https://doi.org/10.1038/nature08646
    54 rdf:type schema:CreativeWork
    55 sg:pub.10.1038/nature09779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050839842
    56 https://doi.org/10.1038/nature09779
    57 rdf:type schema:CreativeWork
    58 sg:pub.10.1038/ncb0502-e131 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026096121
    59 https://doi.org/10.1038/ncb0502-e131
    60 rdf:type schema:CreativeWork
    61 sg:pub.10.1038/ncb1601 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021277213
    62 https://doi.org/10.1038/ncb1601
    63 rdf:type schema:CreativeWork
    64 sg:pub.10.1038/ncb1847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049656389
    65 https://doi.org/10.1038/ncb1847
    66 rdf:type schema:CreativeWork
    67 sg:pub.10.1038/nchembio.391 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020485821
    68 https://doi.org/10.1038/nchembio.391
    69 rdf:type schema:CreativeWork
    70 sg:pub.10.1038/nrc2290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042298247
    71 https://doi.org/10.1038/nrc2290
    72 rdf:type schema:CreativeWork
    73 sg:pub.10.1038/nrc2615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023532012
    74 https://doi.org/10.1038/nrc2615
    75 rdf:type schema:CreativeWork
    76 sg:pub.10.1038/sj.onc.1208841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053064977
    77 https://doi.org/10.1038/sj.onc.1208841
    78 rdf:type schema:CreativeWork
    79 sg:pub.10.1186/bcr2788 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040598960
    80 https://doi.org/10.1186/bcr2788
    81 rdf:type schema:CreativeWork
    82 grid-institutes:grid.239395.7 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...